Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?

Magnetic Resonance Imaging

Volumn 28, Issue 5, 2010, Pages 613-620

  Chen, Wei ^a   Jian, Wang ^a   Li, Hai tao ^a   Li, Chuan ^a   Zhang, Yong ke ^a   Xie, Bin ^a   Zhou, Dai quan ^a   Dai, Yong ming ^b   Lin, Yun ^a   Lu, Ming ^a   Huang, Xue quan ^a   Xu, Chun xia ^a   Chen, Lin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SIEMENS LTD   (China)

Author keywords

Lung cancer; MRI; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CERVICAL LYMPH NODE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; WHOLE BODY IMAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DIAGNOSTIC USE; EVALUATION STUDY; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 77952956085     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2010.02.009     Document Type: Article

References (33)

1. Melamed M.R., Flehinger B.J., Zaman M.B. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am 1987, 67(5):909-924.
2. Pretreatment evaluation of non-small-cell lung cancer The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 1997, 156(1):320-332.
3. Antoch G., et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003, 229(2):526-533.
4. Lardinois D., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003, 348(25):2500-2507.
5. Shim S.S., et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005, 236(3):1011-1019.
6. Cerfolio R.J. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004, 78(3):1017-1023. [discussion 1017-23].
7. Halpern B.S., et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005, 128(4):2289-2297.
8. Lauenstein T.C., et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004, 233(1):139-148.
9. Walker R., et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 2000, 11(4):343-350.
10. Daldrup-Link H.E., et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001, 177(1):229-236.
11. Ohno Y., et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007, 26(3):498-509.
12. Nakanishi K., et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007, 6(3):147-155.
13. Ohno Y., et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008, 248(2):643-654.
14. Tanimoto A., et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007, 25(1):146-152.
15. Matoba M., et al. Lung carcinoma: diffusion-weighted mr imaging-preliminary evaluation with apparent diffusion coefficient. Radiology 2007, 243(2):570-577.
16. Abdel Razek A.A., et al. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006, 16(7):1468-1477.
17. Nasu K., et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006, 239(1):122-130.
18. Charles-Edwards E.M., deSouza N.M. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006, 6:135-143.
19. Takahara T., et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004, 22(4):275-282.
20. Gupta N.C., Graeber G.M., Bishop H.A. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000, 117(3):773-778.
21. Pieterman R.M., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343(4):254-261.
22. Mac Manus M.P., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001, 92(4):886-895.
23. Stroobants S.G., et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. Clin Lung Cancer 2003, 4(4):242-247.
24. Ohno Y., Hatabu H., Takenaka D., et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology 2004, 2004(231):872.
25. Raya J.G., et al. Techniques for diffusion-weighted imaging of bone marrow. Eur J Radiol 2005, 55(1):64-73.
26. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007, 188(6):1622-1635.
27. Koh D.M., et al. Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging. Eur Radiol 2006, 16(9):1898-1905.
28. Gauvain K.M., et al. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol 2001, 177(2):449-454.
29. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 2002, 16(2):196-200.
30. Guo A.C., et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002, 224(1):177-183.
31. Squillaci E., et al. Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res 2004, 24(6):4175-4179.
32. Nomori H., et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 2008, 135(4):816-822.
33. Yi C.A., et al. 3-T MRI: usefulness for evaluating primary lung cancer and small nodules in lobes not containing primary tumors. AJR Am J Roentgenol 2007, 189(2):386-392.